BGM Group Ltd. (BGM) 股票分析

公司概述

BGM Group Ltd. operates as a specialized pharmaceutical and chemical entity based in China, focusing on the production and distribution of oxytetracycline products through its various subsidiaries. The company functions within the broader healthcare sector, specifically categorized under the industry of Drug Manufacturers - Specialty & Generic, which implies a focus on producing specialized medicinal formulations and generic drugs for veterinary and human use. The enterprise is valued with a market capitalization of $61.37M, though specific annual revenue and employee count data are not currently disclosed in the available records. This limited disclosure regarding scale suggests that the company operates as a mid-to-small-cap entity, where the market cap of $61.37M indicates a smaller public footprint compared to large-cap pharmaceutical peers, often reflecting a niche position in the oxytetracycline market rather than broad market dominance.

财务健康

The financial statements for BGM Group Ltd. indicate a Net Income and EBITDA of N/A, while Revenue (TTM) is also listed as N/A, creating a scenario where traditional profitability analysis is constrained by data availability. The absence of reported Net Income and EBITDA figures prevents a direct calculation of the gap between revenue and net income, but the reported Profit Margin of 0.0% and Gross Margin of 0.0% strongly suggest that the company's current cost structure absorbs all revenue or that financial reporting reflects a break-even point in terms of gross profitability before operating expenses are factored in. Free Cash Flow is reported as N/A, which limits the ability to assess immediate financial flexibility through cash generation, though the company holds $14.54M in cash against $1.78M in debt. The balance sheet appears relatively conservative in terms of leverage, evidenced by a Debt to Equity ratio of 0.97, meaning total liabilities are nearly equal to shareholders' equity, yet the substantial cash reserve of $14.54M significantly offsets the $1.78M debt load. Current Ratio data is unavailable, preventing an assessment of short-term liquidity, but the high cash balance relative to total debt implies strong solvency despite the lack of explicit current ratio metrics. Return on Equity and Return on Assets are both N/A, indicating that management effectiveness in generating returns on shareholder capital and total assets cannot be quantified with the provided data, likely due to the N/A status of net income and total equity figures.

估值评估

The trailing P/E ratio and forward P/E for BGM Group Ltd. are both listed as N/A, implying that traditional earnings-based valuation multiples are not applicable or that the company has not generated positive earnings over the trailing twelve months to calculate these ratios. The Price to Book ratio stands at 0.17, a figure that indicates the company is trading at a significant discount to its book value, suggesting the market values the firm at only 17 cents for every dollar of net tangible assets. Price to Sales and EV/EBITDA multiples are also N/A, meaning these alternative valuation metrics cannot be utilized to assess the company's premium or discount relative to peers without earnings or sales data. The stock price has exhibited significant volatility over the last year, trading between a 52-week high of $17.17 and a 52-week low of $0.27. Without the current stock price explicitly listed in the facts, the exact percentage distance from the high or low cannot be calculated, but the range itself highlights the extreme price dispersion typical of small-cap biotech or specialty pharmaceutical stocks. The Beta value is listed as N/A, so the company's price volatility relative to the broader market index cannot be determined from the available information.

Growth & Income

Revenue Growth (YoY) is reported at 13.9%, indicating that the company has successfully expanded its top line by this percentage over the last year, while Earnings Growth (YoY) is N/A due to the lack of reported net income figures. Because earnings growth cannot be quantified against revenue growth, it is impossible to determine if earnings are expanding faster or slower than sales, but the positive revenue trajectory suggests underlying demand for its oxytetracycline products in the veterinary and human markets. As a non-dividend payer with a Dividend Yield of N/A and a Payout Ratio of 0.0%, the company currently retains all of its earnings rather than distributing them to shareholders, which is a common strategy for growth-oriented firms reinvesting capital into R&D or market expansion. The overall growth and income profile is characterized by strong top-line expansion of 13.9% YoY coupled with a complete absence of dividend income and uncertain earnings growth metrics.